#FDA Clearance #Kali Therapeutics #KT501

Kali Therapeutics Achieves FDA Clearance for KT501

Kali Therapeutics, a biotechnology company at the forefront of immune-resetting and multi-specific therapeutic innovations, has announced a significant achievement. On September 3, 2026, the U.S. Food and Drug Administration (FDA) granted clearance for the Investigational New Drug (IND) application for KT501. This novel therapy is now set for clinical development in the United States, aiming to tackle B cell-mediated autoimmune diseases.

What is KT501?

KT501 is a pioneering CD19xBCMAxCD3 tri-specific T-cell engager (TCE). It is designed to effectively target a broad spectrum of B cell populations, including plasma cells, while ensuring minimal toxicity. The tri-specific nature of this antibody allows it to bind to CD19 and BCMA, making it a promising candidate for therapies where existing treatments may have fallen short due to their inability to target all relevant B cells.

This innovative treatment employs a proprietary masking technology to engage CD3, thus maximizing its potency while managing cytokine release. The aim is to achieve deep and multi-targeted B-cell depletion effectively, providing a potentially safer alternative for patients suffering from autoimmune diseases.

Clinical Evaluation and Safety Data

The FDA’s clearance is supported by robust safety, tolerability, pharmacokinetic, and pharmacodynamic data from an ongoing Phase 1a first-in-human trial in Australia, focusing on patients with rheumatoid arthritis (RA). This study, which is currently in an open-label, dose-escalation phase, aims to evaluate the effects of KT501 administered as a single subcutaneous injection.

Dr. Weihao Xu, CEO and Founder of Kali Therapeutics, acknowledges that receiving FDA clearance for KT501 is a pivotal milestone for the company. This achievement not only affirms the safety data from the Australian study but also showcases the potential of Kali's CD3 masking platform. “We are closer to proving that a deep, multi-targeted depletion of B cells can be safely achieved for those living with autoimmune diseases,